ClinicalTrials.gg
RecruitingNCT07879885Updated Oct 20, 2026

An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 2 interventional study of HS-20137 in Moderate-to-severe Plaque Psoriasis, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2025, registered Oct 2026).
  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
390
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited — 7 open to participants now, 7 under way, 2 of them phase 3. Psoriasis · Hansoh Pharmaceutical Group Company Limited.

Planned enrollment
2nd of 10
390 · median 131
Started
2025
with 5 others
Phase 2
4 of 10
4 open now
Registered
10th of 10
by date

Among the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2025, is one of 4 in phase 2, and was the 10th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

7 of the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis

Read the detailed description

HS-20137 is an antibody targeting interleukin-23 (IL-23), a key cytokine involved in the pathogenesis of psoriasis. IL-23-targeting biologic agents are recommended for the treatment of patients with moderate-to-severe psoriasis. This is an open-label, Phase 2, single-arm interventional study, including a 4-week screening period, a 16-week treatment period and a 4-week follow-up period (total 24 weeks). Participants with moderate-to-severe plaque psoriasis will be enrolled in this study and will receive HS-20137 200 mg at weeks 0, 4 and 8. The primary objective is to evaluate the safety and tolerability of HS-20137. Secondary objectives are to evaluate the efficacy and immunogenicity of HS-20137

03

Conditions studied

  • Moderate-to-severe Plaque Psoriasis

Browse trials for

Keywords

  • Plaque Psoriasis; HS-20137; Interleukin-23
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 and above, male or female;
  2. Diagnosed plaque psoriasis for at least 6 months before randomization, with or without psoriatic arthritis;
  3. During screening and randomization, the severity of plaque psoriasis was moderate to severe, and the following conditions should be met: a) BSA≥3%; b) PASI≥3;
  4. Voluntarily participate in the research, have the ability and willingness to complete the research according to the research protocol, and sign the .

Exclusion criteria

Exclusion Criteria:

  1. History of an allergic reaction following prior use of a biologic agent, allergy to known drug components, or a history of severe food or drug allergy;
  2. Confirmation of other types of psoriasis, including but not limited to guttiform psoriasis, pustular psoriasis, erythrodermic psoriasis, drug-induced exacerbation of psoriasis (including beta-blockers, non-steroidal anti-inflammatory drugs, antimalarial drugs, interferon, calcium channel blockers, or lithium induced psoriasis) from the screening period to the time before the first dose;
  3. Other skin lesions, chronic inflammatory diseases or diseases, including but not limited to systemic lupus erythematosus, Sjogren's syndrome, skin sclerosis, etc., assessed by the investigator and other factors that may affect the efficacy evaluation or assessed by other researchers before the first dose;
  4. Primary treatment failure occurred with previous use of similar investigatory drugs (including marketed ulinumab, gusecciumab, Tiricizumab, Lisenciumab, and IL-23 target investigatory drugs under development) (the minimum treatment standard was not reached 12 weeks after the first treatment);
  5. Use of the following drugs before the first dose:

    1. Use of topical treatment drugs that affect the evaluation of psoriasis within 2 weeks before the first dose;
    2. 1 weeks before the first administration, Use of phototherapy, traditional systemic therapy drugs, small molecule targeted drugs that may affect the evaluation of psoriasis;
    3. Prior to the first dose, use of other biologics for the treatment of psoriasis (including but not limited to TNF α inhibitors, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, risankizumab, and IL 23 targeting drugs) without meeting the protocol required time interval for re administration of the original biologic;
    4. use of lymphocyte migration regulators or B cell and T cell regulators (including but not limited to abatacept, telitacicept, etc.), within 3 months before dose, or 6 months before screening, (whichever is older) use of B-cell-specific scavenging drugs (including but not limited to rituximab, inebilizumab, etc.);
  6. A history of chronic recurrent infection, or opportunistic infection in the 6 months prior to screening, or hospitalization for a serious infectious disease or intravenous antibiotic use in the 2 months prior to randomization, with a confirmed or suspected illness in the 1 week prior to the first dose. And Other circumstances determined by the investigator to be unsuitable for further study participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    HS-20137

    Participants receive HS-20137 by subcutaneous injection at weeks 0, 4 and 8

    Biological: HS-20137

Interventions

  • BiologicalHS-20137

    HS-20137 200 mg injection at weeks 0, 4 and 8

    Also known as: QX004N

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    Adverse events will be assessed for incidence, severity, relationship to study intervention, duration, and outcome.

    Time frame: up to 20 weeks

  2. Changes From Baseline in Clinical Laboratory Test Results

    Changes from baseline in protocol-specified clinical laboratory test results following administration of HS-20137 will be assessed.

    Time frame: Frame: up to 20 weeks

  3. Changes From Baseline in Physical Examination Findings

    Changes from baseline in physical examination findings following administration of HS-20137 will be assessed.

    Time frame: up to 20 weeks

  4. Changes From Baseline in Vital Signs

    Changes from baseline in protocol-specified vital signs following administration of HS-20137 will be assessed.

    Time frame: up to 20 weeks

  5. Incidence of Clinically Significant Electrocardiogram (ECG) Abnormalities

    The incidence of clinically significant electrocardiogram (ECG) abnormalities following administration of HS-20137 will be assessed.

    Time frame: up to 20 weeks

Secondary outcomes

  1. PASI 50, PASI 75, PASI 90, and PASI 100 Response Rates at Each Visit Time Point

    The Psoriasis Area and Severity Index (PASI) is a scoring system used to assess the severity of psoriasis based on lesion severity and area of involvement. PASI 50, PASI 75, PASI 90, and PASI 100 response rates are defined as the percentages of participants achieving at least 50%, 75%, 90%, and 100% reduction, respectively, in PASI score from baseline. These response rates will be assessed at each visit time point.

    Time frame: up to 20 weeks

  2. PASI Scores and Changes From Baseline at Each Visit Time Point

    The Psoriasis Area and Severity Index (PASI) score and changes from baseline in PASI score will be assessed at each visit time point.

    Time frame: up to 20 weeks

  3. sPGA 0/1 Response Rate at Each Visit Time Point

    The static Physician's Global Assessment (sPGA) is a 5-point scale ranging from 0 (clear) to 4 (severe) used to assess the overall severity of psoriasis lesions. The sPGA 0/1 response rate is defined as the percentage of participants achieving an sPGA score of 0 (clear) or 1 (almost clear) at each visit time point.

    Time frame: up to 20 weeks

  4. sPGA 0 Response Rate at Each Visit Time Point

    The static Physician's Global Assessment (sPGA) is a 5-point scale ranging from 0 (clear) to 4 (severe) used to assess the overall severity of psoriasis lesions. The sPGA 0 response rate is defined as the percentage of participants achieving an sPGA score of 0 (clear) at each visit time point.

    Time frame: up to 20 weeks

  5. BSA Scores and Changes From Baseline at Each Visit Time Point

    The percentage of body surface area (BSA) affected by psoriasis and changes from baseline in BSA will be assessed at each visit time point.

    Time frame: up to 20 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 19 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2026
First posted
Oct 19, 2026
StartActual
Jul 31, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07879885
Responsible party
Sponsor
First posted
Oct 19, 2026
Start date
Jul 31, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion